1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
The Alzheimer's Drug Discovery Foundation Drug Development RFP provides substantial funding of up to $5 million for IND-enabling studies and early-phase clinical trials targeting Alzheimer's disease and related dementias. The program operates as a venture philanthropy model, supporting novel drug development approaches including AI-driven computational drug discovery, target identification, and molecular modeling.
Priority research areas include combination therapies, epigenetics, inflammation, mitochondrial function, neuroprotection, proteostasis, and aging-related mechanisms. The ADDF accepts proposals for Phase 0, Phase 1, and biomarker-based proof-of-concept studies, as well as pharmacology, toxicology, and manufacturing studies. The foundation funds novel, repurposed, and repositioned drugs, natural products, and devices.
Both academic medical centers and biotechnology companies (including new AI-driven drug discovery startups) are eligible. The program uses a two-stage review process with letters of intent due September 14, 2026, followed by invited full proposals. As a mission-related investment, funding may include return-on-investment requirements based on scientific and business milestones, distinguishing it from traditional grants.
Get alerted about grants like this
Save a search for “Alzheimer's Drug Discovery Foundation (ADDF)” or related topics and get emailed when new opportunities appear.
Search similar grants →According to the current listing, eligibility includes: Open to researchers and clinicians worldwide at academic medical centers, universities, nonprofits, and biotechnology companies (both existing companies and new startups). Industry partnerships are encouraged. Funding operates as mission-related investments requiring return on investment based on scientific and business milestones. Confirm the full requirements in the official notice before applying.
The current listing shows up to $5,000,000 per award based on stage and scope of research. Operates as venture philanthropy with milestone-based funding. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for ADDF Drug Development RFP for AI-Enabled Alzheimer's and Neurodegeneration Drug Discovery are due September 14, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
ADDF Drug Development RFP for AI-Enabled Alzheimer's and Neurodegeneration Drug Discovery is funded by Alzheimer's Drug Discovery Foundation (ADDF). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
ADDF-Harrington Scholar Program RFP is sponsored by Alzheimer's Drug Discovery Foundation (ADDF) and Harrington Discovery Institute. This program provides funding and drug development support for research efforts aimed at treating or preventing Alzheimer's disease, related dementias, and cognitive decline associated with aging. The award includes a two-year grant, funding, opportunity for investment funds, and comprehensive drug development expertise and support.
The ADDF-Harrington Scholar Program identifies and accelerates promising drug discovery research for Alzheimer's disease and related dementias, with explicit support for AI/ML-enabled approaches including generative AI for novel drug candidate identification, deep learning for target validation, AI-driven repurposing of approved drugs, and computational platforms for amyloid and tau pathology. Scholars receive a 2-year grant of $600K plus comprehensive drug development expertise from the Harrington Discovery Institute and ADDF's Drug Development Accelerator. Optional follow-on investment through ADDF's venture arm. Strong fit for academic investigators with promising preclinical leads, AI-enabled drug discovery platforms, or novel computational therapeutic approaches.
Healthy School Awards Program is sponsored by Blue Cross & Blue Shield Of Mississippi Foundation. Recognizes and rewards public K-12 schools in Mississippi that encourage healthy lifestyle behaviors and implement exemplary school health and wellness initiatives. Awards are given in categories based on school enrollment size, with one school designated as the Healthiest School in Mississippi. Geographic focus: Mississippi Focus areas: Healthy Eating, Physical Activity, Staff Wellness, Tobacco-Free Lifestyles
The Community Grants (New York and Pennsylvania Regions) program is a grant from the William G. McGowan Charitable Fund that supports nonprofits working in Monroe or Yates County, New York, or Lackawanna or Luzerne County, Pennsylvania. Grants average approximately $28,000 and can range from small amounts to six-figure commitments for program or operations support. Eligible applicants are 501(c)(3) organizations whose work addresses the foundation's goals. First-time applicants must submit a Letter of Inquiry (LOI) before applying. The April 2026 application deadline has passed; inquiries are also accepted on a rolling basis for future cycles.
ARPA-H's new Intelligent Generator of Research program will fund ~3 teams to build an AI-powered research ecosystem. Solution summaries due June 25, 2026.
Read articleThe DOE Genesis Mission offers $293M for AI-driven research across 20+ fields from quantum science to nuclear energy. Phase I applications due April 28, 2026.
Read articleARPA-H PROSPR program funds seven research teams testing rapamycin, semaglutide, and novel compounds to extend healthspan. A deep analysis of the science, the money, and what it means for the field.
Read article